| Tiffany Anne Vaughn, | |
|
1304 Oak St, Melbourne, FL 32901-3111 | |
| (321) 723-4723 | |
| (321) 727-1448 |
| Full Name | Tiffany Anne Vaughn |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 12 Years |
| Location | 1304 Oak St, Melbourne, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225383318 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | ARNP3056752 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Steward Sebastian River Medical Center | Sebastian, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Steward Anesthesiology Physicians Of Florida Inc. | 2860813011 | 19 |
News Archive
Scientists are warning of the increasing threat from infections caused by antibiotic-resistant Escherichia coli (E. coli) bacteria.
Lobbying campaigns and legislative battles have been underway for months as Congress tries to solve the problem of surprise billing, when patients face often exorbitant costs after they unknowingly receive care from an out-of-network doctor or hospital.
DSM Biologics is pleased to announce the signing of preliminary agreements to enter a partnership with the Australian Governments (Queensland State Government and the Commonwealth of Australia) to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane.
In what is being hailed as a significant advance in the treatment of children with sickle cell anemia, a drug commonly used to treat adults has been shown to be safe and effective in children.
Gilead Sciences, Inc. today announced the presentation of three-year (144-week) open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.
› Verified 4 days ago
| Entity Name | Brevard Physician Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598008955 PECOS PAC ID: 1850535048 Enrollment ID: O20130909000619 |
News Archive
Scientists are warning of the increasing threat from infections caused by antibiotic-resistant Escherichia coli (E. coli) bacteria.
Lobbying campaigns and legislative battles have been underway for months as Congress tries to solve the problem of surprise billing, when patients face often exorbitant costs after they unknowingly receive care from an out-of-network doctor or hospital.
DSM Biologics is pleased to announce the signing of preliminary agreements to enter a partnership with the Australian Governments (Queensland State Government and the Commonwealth of Australia) to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane.
In what is being hailed as a significant advance in the treatment of children with sickle cell anemia, a drug commonly used to treat adults has been shown to be safe and effective in children.
Gilead Sciences, Inc. today announced the presentation of three-year (144-week) open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.
› Verified 4 days ago
| Entity Name | Steward Anesthesiology Physicians Of Florida Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336786029 PECOS PAC ID: 2860813011 Enrollment ID: O20200527000121 |
News Archive
Scientists are warning of the increasing threat from infections caused by antibiotic-resistant Escherichia coli (E. coli) bacteria.
Lobbying campaigns and legislative battles have been underway for months as Congress tries to solve the problem of surprise billing, when patients face often exorbitant costs after they unknowingly receive care from an out-of-network doctor or hospital.
DSM Biologics is pleased to announce the signing of preliminary agreements to enter a partnership with the Australian Governments (Queensland State Government and the Commonwealth of Australia) to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane.
In what is being hailed as a significant advance in the treatment of children with sickle cell anemia, a drug commonly used to treat adults has been shown to be safe and effective in children.
Gilead Sciences, Inc. today announced the presentation of three-year (144-week) open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tiffany Anne Vaughn, 1304 Oak St, Melbourne, FL 32901-3111 Ph: (321) 723-4723 | Tiffany Anne Vaughn, 1304 Oak St, Melbourne, FL 32901-3111 Ph: (321) 723-4723 |
News Archive
Scientists are warning of the increasing threat from infections caused by antibiotic-resistant Escherichia coli (E. coli) bacteria.
Lobbying campaigns and legislative battles have been underway for months as Congress tries to solve the problem of surprise billing, when patients face often exorbitant costs after they unknowingly receive care from an out-of-network doctor or hospital.
DSM Biologics is pleased to announce the signing of preliminary agreements to enter a partnership with the Australian Governments (Queensland State Government and the Commonwealth of Australia) to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane.
In what is being hailed as a significant advance in the treatment of children with sickle cell anemia, a drug commonly used to treat adults has been shown to be safe and effective in children.
Gilead Sciences, Inc. today announced the presentation of three-year (144-week) open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.
› Verified 4 days ago
Barry T Roberts, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1304 Oak St, Melbourne, FL 32901 Phone: 321-723-4723 Fax: 321-727-1448 | |
Thomas Harold Pierce, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2134 Nebula Way Unit 101, Melbourne, FL 32904 Phone: 256-990-5466 | |
Patricia Ann Sullivan-liebig, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 282 Oak Haven Dr, Melbourne, FL 32940 Phone: 321-863-6531 Fax: 321-254-6196 | |
Sandra Jean Bess, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 625 Sandpiper Cir, Melbourne, FL 32901 Phone: 321-727-8071 Fax: 321-727-8071 | |
Christine L Croskey, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1340 Medical Park Dr, Ste 101, Melbourne, FL 32901 Phone: 321-729-9493 | |
Patricia Navara, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1304 Oak St, Melbourne, FL 32901 Phone: 321-723-4723 Fax: 321-727-1448 | |
Kandee G Coppala, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1304 Oak St, Melbourne, FL 32901 Phone: 321-723-4723 Fax: 321-727-1448 |